Skip to content

Dual Task Training in Parkinson's Disease

Effect of Dual Task Training on Balance, Gait, Cognition and Neurotrophic Factors in Parkinson's Disease

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04115683
Enrollment
20
Registered
2019-10-04
Start date
2019-10-16
Completion date
2021-06-30
Last updated
2019-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Brief summary

The aim of study is to analyze the effects of dual task training on balance, gait, cognition and neurotrophic factors in Parkinson's disease.

Detailed description

20 patients diagnosed with Parkinson's disease will be randomly assigned to either intervention or control group. And 10 healty subjects will be included to study in order to determine the reference values.The intervention group will be recieved cognitive and motor dual task training consisting of balance and walking activities 3 days a week for 8 weeks. Control group will be recieved same balance and walking activities in single task condition 3 days a week for 8 weeks. In order to evaluate the effects of the training, evaluations will be performed before and after the training period.

Interventions

OTHERDual Task Training

45 minutes of dual task training consisting of motor activities (walking, balance... etc.) with combination of cognitive activities (spelling words, image description, nomination, word generation, counting... etc.) at sime time.

45 minutes of single task training consisting of same motor activities (walking, balance... etc.)

Sponsors

Gazi University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* at least 40 years of age * neurologist-diagnosed Parkinson's Disease * Hoehn & Yahr (H&Y) stages 1 to 3 * 24 or more mini mental status examination score.

Exclusion criteria

* other neurologic disorder * cardiovascular, inflammatory,vestibular or musculoskeletal problems that could prevent them to participate in an exercise program * had deep brain stimulation history * visual, auditory, orientational problems that could affect study results

Design outcomes

Primary

MeasureTime frameDescription
Change in insulin like growth factor 1 (IGF-1) levels of serum8 weeksInsulin like growth factor 1 (IGF-1) levels of serum will be measured by using sandwich enzyme-linked immunosorbent assay (ELISA) kit.
Balance- Limits of Stability8 weeksLimits of Stability will be evaluated with Biodex Biosway Portable Balance System (Biodex Medical Systems Inc., Shirley, New York). Limits of Stability test assesses how much the center of gravity is displaced on the support surface without losing balance during the standing position. Total direction control score will obtained as the test result.
Balance- Modified Sensory Organization Tests8 weeksModified Sensory Organization Tests will be evaluated Biodex Biosway Portable Balance System (Biodex Medical Systems Inc., Shirley, New York). MSOT assesses the effects of somatosensory, visual and vestibular senses on postural control during the standing position. It evaluates the sensory component of balance in two different visual conditions and on two different support surfaces; condition 1: eyes open-firm surface, condition 2: eyes closed-firm surface, condition 3: eyes open-foam surface and condition 4: eyes closed-foam surface. Stability index scores will obtained as the test result.
Gait Speed8 weeksGait speed will be evaluated by using the BTS-G Walk system and recorded as m/min. It is a wireless system positioned on L5 vertebrae of the spine. It allows a functional objective gait analysis to be performed.
Cadence8 weeksCadence will be evaluated by using the BTS-G Walk system and recorded as strides/min. It is a wireless system positioned on L5 vertebrae of the spine. It allows a functional objective gait analysis to be performed.
Stride width8 weeksStride width will be evaluated by using the BTS-G Walk system and recorded as meters. It is a wireless system positioned on L5 vertebrae of the spine. It allows a functional objective gait analysis to be performed.
Stride length8 weeksStride length will be evaluated by using the BTS-G Walk system and recorded as meters. It is a wireless system positioned on L5 vertebrae of the spine. It allows a functional objective gait analysis to be performed.
Montreal Cognitive Assessment (MoCA)8 weeksMontreal Cognitive Assessment (MoCA) will be used in order to evaluate cognition. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation.It' score ranged from 0 to 30 and higher points indicates better cognitive outcomes.
Change in brain derived neurotrophic factor (BDNF) levels of serum8 weeksBrain derived neurotrophic factor (BDNF) levels of serum will be measured by using sandwich enzyme-linked immunosorbent assay (ELISA) kit.
Change in vascular endothelial growth factor (VEGF) levels of serum8 weeksVascular endothelial growth factor (VEGF) levels of serum will be measured by using sandwich enzyme-linked immunosorbent assay (ELISA) kit.
Balance-Postural Stability8 weeksPostural Stability will be evaluated with Biodex Biosway Portable Balance System (Biodex Medical Systems Inc., Shirley, New York).. Postural Stability test will performed on both feet and on the left and right foot separately. Total stability index score will obtained as the test result.

Secondary

MeasureTime frameDescription
Unified Parkinson's Disease Rating Scale (UPDRS)8 weeksThe Unified Parkinson's Disease Rating Scale (UPDRS) is a widely used measure of impairment and disability associated with Parkinson's Disease (PD) consisting of four sections: (1) Mentation, behavior, and mood; (2) Activities of daily living (ADLs); (3) Motor; and (4) Complications.Sections I through III are scored using a 5-point Likert-type scale (0 = no impairment; 4 = marked impairment). Although individual sections are scored and reported independently, scores from sections I through III are also summed to provide a UPDRS Total score. The UPDRS total score ranges between 0 and 199 points. Higher points indicates worse outcome.
Berg Balance Scale (BBS)8 weeksBerg Balance Scale (BBS) is a scale that using for assess postural stability. It ranges 0-56 with higher score indicates better stability.
One-legged Stance Test8 weeksThe duration participant is able to maintain their balance on one leg up to will be recorded.
Timed Up and Go (TUG) test8 weeksTime in seconds a person needs to stand up from a chair, walk a distance of 3 meters, turn around a flag, come back and sit down again.
Activities-Specific Balance Confidence (ABC) Scale8 weeksActivities-specific Balance Confidence scale (ABC), to quantify the level of confidence in performing a specific task without losing balance or becoming unsteady.
Stroop Test8 weeksStroop test will be used to test cognitive function.
Trail Making Test (TMT) Part A and B8 weeksThe Trail Making Test is a measure of attention, speed and mental flexibility.
Short-Form 8-Item Parkinson's Disease Questionnaire (PDQ-8)8 weeksThe short-form 8-item Parkinson's disease Questionnaire (PDQ-8) is the most commonly used scale measuring health related quality of life (HRQoL) in PD patients. It includes 8 items, and each item has five options (never, occasionally, sometimes, often, always or cannot do at all). The total score ranges from 0 to 32. Higher scores indicates poorer quality of life.
Hoehn and Yahr Scale for level of physical disability in Parkinson's disease.8 weeksHoehn and Yahr Scale is measures level of physical disability in Parkinson's disease and stages patients between level 1 level 5. Higher level indicates worse physical condition.

Countries

Turkey (Türkiye)

Contacts

Primary ContactÇağrı Gülşen, MSc
fztcagri@gmail.com05555874415

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026